You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Spread Spectrum Techniques for Sonar Ping Technology

    SBC: 3 Phoenix, Inc.            Topic: N101005

    The operational need for the Non-Traditional Sensor System (NTSS) technology insertion initiative addresses the need to improve detection of quiet threat submarines in both shallow and deep water environments, and represents a critical submarine capability enhancement. The primary goal is to mature the NTSS design under this SBIR and to ultimately integrated into NTSS capability into US Navy subma ...

    SBIR Phase II 2012 Department of DefenseNavy
  2. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    SBC: NEUROP, INC.            Topic: 102

    DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a stroke each year at an estimated annual cost of $ B American Heart Association Heart Disease and Stroke Statistics Update Substantial preclinical data support the use of NMDA receptor antago ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea

    SBC: SELEXYS PHARMACEUTICALS CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance SelG1 into Phase II/III safety and efficacy trials to support of regulatory filings for FDA approval ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Automated Analysis and Verification of Application Program Interfaces (APIs)

    SBC: TRIDENT SYSTEMS LLC            Topic: N093227

    Fully retesting a modified system is frequently not economically feasible. Thorough retesting takes too much time and costs too much.Trident has established a process and methodology, called Safe Test Boundaries (STB) that improves retesting modified baseline systems. The methodology defines a safe test boundary around the modified and impacted cooperating units interacting with the baseline syste ...

    SBIR Phase II 2012 Department of DefenseNavy
  5. Adaptive Data Fusion for Real-time Threat Assessment

    SBC: 3 Phoenix, Inc.            Topic: N103224

    We propose a data fusion framework that is appropriate for an adaptive classifier implemented with supervised and multi-task learning. The detection and data fusion (DDF) engine will map the results of advanced feature extraction algorithms (weighted multi-dimensional feature vectors) onto a nonlinear vector space which will increase separation and improve Pcc. We will investigate several differen ...

    SBIR Phase II 2012 Department of DefenseNavy
  6. Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme

    SBC: NEUROP, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a stroke each year at an estimated annual cost of 73.7B (American Heart Association. Heart Disease and Stroke Statistics, 2010 Update). Substantial preclinical data support the use of NMDA receptor antago ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Long Endurance Hovering Surveillance Platform / Urban Beat Cop

    SBC: AURORA FLIGHT SCIENCES CORPORATION            Topic: N102172

    ABSTRACT: Collecting information in an urban environment is done in non-combat operations on a daily basis by local law enforcement by officers walking the beat. Officers are present on our streets. Officers become familiar with areas of the city by constantly understanding and interpreting what they see on a daily basis. A system that can perform this same mission in evolving urban conflicts, ...

    SBIR Phase II 2012 Department of DefenseAir Force
  8. Clean, Green, ChemBio Defense/Fire Retardant Process Using Nanotechnology

    SBC: Aqua Resources Corporation            Topic: SOCOM10007

    NanoPlatelets (NPs) created of metal hydroxides present entirely new and previously unknown set of morphologes/properties and are a virtually new frontier and unstudied field of Material Science and may be leveraged into many of todays DoD and Comercial Technical Challenges and applications. Case in point is SOCOM's Defense Mitigation and Decontamination of military aircraft and equipment and ...

    SBIR Phase II 2012 Department of DefenseSpecial Operations Command
  9. Levodopa Pharmacokinetic Optimization by Metal Coordination

    SBC: Synthonics, Inc.            Topic: 104

    DESCRIPTION provided by applicant Synthonics is developing the metal coordinated levodopa drug product MCP for FDA approval Levodopa has served as a primary pharmacotherapy for patients with Parkinsonandapos s disease PD for years and it remains uniquely effective However replacing dopamine by administering levodopa in a standard formulations results in pulsatile delivery charact ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Levodopa Pharmacokinetic Optimization by Metal Coordination

    SBC: Synthonics, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Synthonics is developing the metal-coordinated levodopa drug product, MCP-311, for FDA approval. Levodopa has served as a primary pharmacotherapy for patients with Parkinson's disease (PD) for 40 years and it remains uniquely effective. However, replacing dopamine by administering levodopa in a standard formulations results in pulsatile delivery, character ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government